KASL clinical practice guidelines for liver cirrhosis: Ascites and related complications

키워드

참고문헌 (242)

1. Guyatt GH, "GRADE: an emerging consensus on rating quality of evidence and strength of recommendations", BMJ, 336, pp.924~926 (2008)[DOI]
2. Falade-Nwulia O, "Oral direct-acting agent therapy for hepatitis C virus infection: a systematic review", Ann Intern Med, 166, pp.637~648 (2017)[DOI]
3. "Sovaldi(R) (sofosbuvir), prescribing information"[URL]
4. "Daklinza(R) (daclatasvir), prescribing information"[URL]
5. "Viekira(R) (dasabuvir, ombitasvir, paritaprevir, and ritonavir), prescribing information"[URL]
6. "Zepatier(R) (elbasvir and grazoprevir), prescribing information"[URL]
7. "Mavyret(R) (glecaprevir and pibrentasvir), prescribing information"[URL]
8. "Epclusa(R) (sofosbuvir and velpatasvir), prescribing information"[URL]
9. Pawlotsky JM, "Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens", Gastroenterology, 151, pp.70~86 (2016)[DOI]
10. Sarrazin C, "The importance of resistance to direct antiviral drugs in HCV infection in clinical practice", J Hepatol, 64, pp.486~504 (2016)[DOI]
11. "Hepatology", 2015, 322A~
12. Manns M, "All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study", Lancet, 384, pp.1597~1605 (2014)[DOI]
13. Zeuzem S, "Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial", Ann Intern Med, 163, pp.1~13 (2015)[DOI]
14. Afdhal N, "Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection", N Engl J Med, 370, pp.1889~1898 (2014)[DOI]
15. Kowdley KV, "Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis", N Engl J Med, 370, pp.1879~1888 (2014)[DOI]
16. Ingiliz P, "Sofosbuvir and ledipasvir for 8 Weeks for the treatment of chronic hepatitis C virus (HCV) infection in HCV-monoinfected and HIVHCV-coinfected individuals: results from the German hepatitis C cohort (GECCO-01)", Clin Infect Dis, 63, pp.1320~1324 (2016)[DOI]
17. Zeng QL, "Generic ledipasvir-sofosbuvir for patients with chronic hepatitis C: a reallife observational study", J Hepatol, 66, pp.1123~1129 (2017)[DOI]
18. Backus LI, "Realworld effectiveness of ledipasvir", sofosbuvir in 4,365 treatmentnaive, genotype 1 hepatitis C-infected patients, 2016, pp.64, 405~414
19. Kowdley KV, "Eight weeks of ledipasvir", sofosbuvir is effective for selected patients with genotype 1 hepatitis C virus infection, 2017, pp.65, 1094~1103
20. Zeuzem S, "NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: prevalence and effect on treatment outcome", J Hepatol, 66, pp.910~918 (2017)[DOI]
21. Ogawa E, "NS5A resistance-associated variants undermine the effectiveness of ledipasvir and sofosbuvir for cirrhotic patients infected with HCV genotype 1b", J Gastroenterol, 52, pp.845~854 (2017)[DOI]
22. Sperl J, "Efficacy and safety of elbasvir", grazoprevir and sofosbuvir, ribavirin: a phase III randomized controlled trial, pp.J Hepatol, 2016[DOI]
23. Kumada H, "The combination of elbasvir and grazoprevir for the treatment of chronic HCV infection in Japanese patients: a randomized phase II", III study, 2017, pp.52, 520~533
24. Komatsu TE, "Regulatory analysis of effects of hepatitis C virus NS5A polymorphisms on efficacy of elbasvir and grazoprevir", Gastroenterology, 152, pp.586~597 (2017)[DOI]
25. Ferenci P, "ABT-450", r-ombitasvir and dasabuvir with or without ribavirin for HCV, 2014, pp.370, 1983~1992
26. Dore GJ, "Efficacy and safety of ombitasvir", paritaprevir, II trials, pp.J Hepatol, 2016[DOI]
27. Poordad F, "ABT-450", r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis, 2014, pp.370, 1973~1982
28. Feld JJ, "Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir", paritaprevir, J Hepatol, pp.2016, 64[DOI]
29. Luetkemeyer AF, "12 weeks of daclatasvir in combination with sofosbuvir for HIV-HCV coinfection (ALLY-2 Study): efficacy and safety by HIV combination antiretroviral regimens", Clin Infect Dis, 62, pp.1489~1496 (2016)[DOI]
30. Wyles DL, "Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1", N Engl J Med, 373, pp.714~725 (2015)[DOI]
31. Sulkowski MS, "Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection", N Engl J Med, 370, pp.211~221 (2014)[DOI]
32. Pol S, "Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients", J Hepatol, 66, pp.39~47 (2017)[DOI]
33. Poordad F, "Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence", Hepatology, 63, pp.1493~1505 (2016)[DOI]
34. McPhee F, "High sustained virologic response to daclatasvir plus asunaprevir in elderly and cirrhotic patients with hepatitis C virus genotype 1b without baseline NS5A polymorphisms", Adv Ther, 32, pp.637~649 (2015)[DOI]
35. Kao JH, "All-oral daclatasvir plus asunaprevir for chronic hepatitis C virus (HCV) genotype 1b infection: a sub-analysis in Asian patients from the HALLMARK DUAL study", Liver Int, 36, pp.1433~1441 (2016)[DOI]
36. Kwo PY, "Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis", J Hepatol, 67, pp.263~271 (2017)[DOI]
37. "Hepatology", 2016, 132A~133A
38. "J Hepatol", 2017, S721~
39. Gane E, "High efficacy of ABT-493 and ABT-530 treatment in patients with HCV genotype 1 or 3 infection and compensated cirrhosis", Gastroenterology, 151, pp.651~659 (2016)[DOI]
40. Forns X, "Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial", Lancet Infect Dis, 17, pp.1062~1068 (2017)[DOI]
41. Chayama K, "Efficacy and safety of glecaprevir", pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis, 2018, pp.53, 557~565
42. Feld JJ, "Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection", N Engl J Med, 373, pp.2599~2607 (2015)[DOI]
43. Jacobson IM, "Efficacy of 8 weeks of sofosbuvir, velpatasvir, and voxilaprevir in patients with chronic HCV infection: 2 phase 3 randomized trials", Gastroenterology, 153, pp.113~122 (2017)[DOI]
44. Afdhal N, "Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection", N Engl J Med, 370, pp.1483~1493 (2014)[DOI]
45. Bourliere M, "Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis nonresponsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS)", Lancet Infect Dis, 15, pp.397~404 (2015)[DOI]
46. Mizokami M, "Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial", Lancet Infect Dis, 15, pp.645~653 (2015)[DOI]
47. Lim YS, "A phase IIIb study of ledipasvir", sofosbuvir fixed-dose combination tablet in treatment-naive and treatment-experienced Korean patients chronically infected with genotype 1 hepatitis C virus, 2016, pp.10, 947~955
48. Sarrazin C, "Prevalence of resistance-associated substitutions in HCV NS5A, NS5B, or NS3 and outcomes of treatment with ledipasvir and sofosbuvir", Gastroenterology, 151, pp.501~512 (2016)[DOI]
49. Kwo P, "Effectiveness of elbasvir and grazoprevir combination, with or without ribavirin, for treatment-experienced patients with chronic hepatitis C infection", Gastroenterology, 152, pp.164~175 (2017)[DOI]
50. Zeuzem S, "Retreatment of HCV with ABT-450", r-ombitasvir and dasabuvir with ribavirin, 2014, pp.370, 1604~1614
51. Andreone P, "ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection", Gastroenterology, 147, pp.359~365 (2014)[DOI]
52. Kumada H, "Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection", Hepatology, 59, pp.2083~2091 (2014)[DOI]
53. Wang HL, "Effectiveness and safety of daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: Systematic review and meta-analysis", J Gastroenterol Hepatol, 32, pp.45~52 (2017)[DOI]
54. "Clin Mol Hepatol", 2017, 59A~
55. "Clin Mol Hepatol", 2017, 63A~
56. Pianko S, "Sofosbuvir plus velpatasvir combination therapy for treatmentexperienced patients with genotype 1 or 3 hepatitis C virus infection: a randomized trial", Ann Intern Med, 163, pp.809~817 (2015)[DOI]
57. Alqahtani SA, "Safety and tolerability of ledipasvir", sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trials, 2015, pp.62, 25~30
58. Lawitz E, "Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial", Lancet, 385, pp.1075~1086 (2015)[DOI]
59. "Hepatology", 2015, 1393A~1394A
60. "Hepatology", 2015, 556A~557A
61. Feld JJ, "Treatment of HCV with ABT-450", r-ombitasvir and dasabuvir with ribavirin, 2014, pp.370, 1594~1603
62. Jacobson IM, "Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options", N Engl J Med, 368, pp.1867~1877 (2013)[DOI]
63. Ahn SH, "A phase 3b study of sofosbuvir plus ribavirin in treatment-naive and treatment-experienced Korean patients chronically infected with genotype 2 hepatitis C virus", J Viral Hepat, 23, pp.358~365 (2016)[DOI]
64. Omata M, "Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open-label, phase 3 trial", J Viral Hepat, 21, pp.762~768 (2014)[DOI]
65. Zeuzem S, "Sofosbuvir and ribavirin in HCV genotypes 2 and 3", N Engl J Med, 370, pp.1993~2001 (2014)[DOI]
66. "Clin Mol Hepatol", 2017, 62A~63A
67. Welzel TM, "Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study", Gut, 66, pp.1844~1852 (2017)[DOI]
68. Mangia A, "Sofosbuvir and ribavirin for genotype 2 HCV infected patients with cirrhosis: a real life experience", J Hepatol, 66, pp.711~717 (2017)[DOI]
69. Ippolito AM, "HCV clearance after direct-acting antivirals in patients with cirrhosis by stages of liver impairment: the ITAL-C network study", Dig Liver Dis, 49, pp.1022~1028 (2017)[DOI]
70. Foster GR, "Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection", N Engl J Med, 373, pp.2608~2617 (2015)[DOI]
71. "J Hepatol", 2016, S787~S788
72. Lee S, "Efficacy and tolerability of pegylated interferon-alpha2a plus ribavirin versus pegylated interferon-alpha2b plus ribavirin in treatment-naive chronic hepatitis C patients", Intervirology, 53, pp.146~153 (2010)[DOI]
73. 박상훈, "Efficacy and Tolerability of Peginterferon Alpha Plus Ribavirin in the Routine Daily Treatment of Chronic Hepatitis C Patients in Korea: A Multi-Center, Retrospective Observational Study", Gut and Liver, 6(1), pp.98~106 (2012), 거트앤리버 소화기연관학회협의회
74. Ferenci P, "A randomized, prospective trial of ribavirin 400 mg", day versus 800 mg, Hepatology, pp.2008, 47[DOI]
75. Fried MW, "Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection", N Engl J Med, 347, pp.975~982 (2002)[DOI]
76. Hadziyannis SJ, "Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose", Ann Intern Med, 140, pp.346~355 (2004)[DOI]
77. Jacobson IM, "Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial", Hepatology, 46, pp.971~981 (2007)[DOI]
78. Manns MP, "Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial", Lancet, 358, pp.958~965 (2001)[DOI]
79. Zeuzem S, "Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3", J Hepatol, 40, pp.993~999 (2004)[DOI]
80. Foster GR, "Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection", Gastroenterology, 149, pp.1462~1470 (2015)[DOI]
81. Gane EJ, "Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection", Gastroenterology, 149, pp.1454~1461 (2015)[DOI]
82. Gao M, "Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect", Nature, 465, pp.96~100 (2010)[DOI]
83. Nelson DR, "All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study", Hepatology, 61, pp.1127~1135 (2015)[DOI]
84. Leroy V, "Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: a randomized phase III study (ALLY-3+)", Hepatology, 63, pp.1430~1441 (2016)[DOI]
85. Alonso S, "Effectiveness and safety of sofosbuvir-based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection and cirrhosis. Results of a multicenter real-life cohort", J Viral Hepat, 24, pp.304~311 (2017)[DOI]
86. Welzel TM, "Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort", Gut, 65, pp.1861~1870 (2016)[DOI]
87. "J Hepatol", 2017, S33~
88. Gane EJ, "Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C", N Engl J Med, 368, pp.34~44 (2013)[DOI]
89. Lawitz E, "Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial", Lancet Infect Dis, 13, pp.401~408 (2013)[DOI]
90. Dalgard O, "Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response", Hepatology, 47, pp.35~42 (2008)
91. Mangia A, "Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3", N Engl J Med, 352, pp.2609~2617 (2005)[DOI]
92. Shiffman ML, "Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3", N Engl J Med, 357, pp.124~134 (2007)[DOI]
93. Hezode C, "Daclatasvir plus sofosbuvir, with or without ribavirin, for hepatitis C virus genotype 3 in a French early access programme", Liver Int, 37, pp.1314~1324 (2017)[DOI]
94. "J Hepatol", 2017, S503~S504
95. "Hepatology", 2016, 62A~63A
96. Kohli A, "Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof-ofconcept, single-centre, open-label phase 2a cohort study", Lancet Infect Dis, 15, pp.1049~1054 (2015)[DOI]
97. Abergel A, "Ledipasvir plus sofosbuvir for 12 weeks in patients with hepatitis C genotype 4 infection", Hepatology, 64, pp.1049~1056 (2016)
98. "Hepatology", 2015, 340A~
99. Rockstroh JK, "Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial", Lancet HIV, 2, pp.e319~e327 (2015)[DOI]
100. Hezode C, "Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial", Lancet, 385, pp.2502~2509 (2015)[DOI]
101. "Hepatology", 2016, 63A~, 10.1002[DOI]
102. "The International Liver Congress(TM) 2015-50th Annual meeting of the European Association for the Study of the Liver", 2015, S278~
103. "J Hepatol", 2016, S755~
104. Abergel A, "Ledipasvir-sofosbuvir in patients with hepatitis C virus genotype 5 infection: an open-label, multicentre, single-arm, phase 2 study", Lancet Infect Dis, 16, pp.459~464 (2016)[DOI]
105. Wyles D, "Sofosbuvir and velpatasvir for the treatment of hepatitis C virus in patients coinfected with human immunodeficiency virus type 1: an open-label, phase 3 study", Clin Infect Dis, 65, pp.6~12 (2017)[DOI]
106. Nguyen MH, "Chronic hepatitis C: genotypes 4 to 9", Clin Liver Dis, 9, pp.411~426 (2005)[DOI]
107. Wong RJ, "Community-based real-world treatment outcomes of sofosbuvir", ledipasvir in Asians with chronic hepatitis C virus genotype 6 in the United States, 2017, pp.24, 17~21
108. Nguyen NH, "Response to pegylated interferon and ribavirin in Asian American patients with chronic hepatitis C genotypes 1 vs 2", 3 vs 6, 2010, pp.17, 691~697
109. Tsang OT, "Chronic hepatitis C genotype 6 responds better to pegylated interferon and ribavirin combination therapy than genotype 1", J Gastroenterol Hepatol, 25, pp.766~771 (2010)[DOI]
110. Yuen MF, "Response to combined interferon and ribavirin is better in patients infected with hepatitis C virus genotype 6 than genotype 1 in Hong Kong", Intervirology, 49, pp.96~98 (2006)[DOI]
111. Bunchorntavakul C, "Treat chronic hepatitis C virus infection in decompensated cirrhosis - pre- or post-liver transplantation? the ironic conundrum in the era of effective and well-tolerated therapy", J Viral Hepat, 23, pp.408~418 (2016)[DOI]
112. Charlton M, "Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease", Gastroenterology, 149, pp.649~659 (2015)[DOI]
113. Curry MP, "Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis", N Engl J Med, 373, pp.2618~2628 (2015)[DOI]
114. Foster GR, "Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis", J Hepatol, 64, pp.1224~1231 (2016)[DOI]
115. "Hepatology", 2015, 738A~
116. "HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C"[URL]
117. "J Hepatol", 2016, S120~S129, 10.1016[DOI]
118. Garcia-Retortillo M, "Hepatitis C virus kinetics during and immediately after liver transplantation", Hepatology, 35, pp.680~687 (2002)[DOI]
119. Forman LM, "The association between hepatitis C infection and survival after orthotopic liver transplantation", Gastroenterology, 122, pp.889~896 (2002)[DOI]
120. Gane EJ, "Long-term outcome of hepatitis C infection after liver transplantation", N Engl J Med, 334, pp.815~820 (1996)[DOI]
121. Curry MP, "Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study", Gastroenterology, 148, pp.100~107 (2015)[DOI]
122. Belli LS, "ELITA consensus statements on the use of DAAs in liver transplant candidates and recipients", J Hepatol, 67, pp.585~602 (2017)[DOI]
123. Manns M, "Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial", Lancet Infect Dis, 16, pp.685~697 (2016)[DOI]
124. "J Hepatol", 2017, S90~S91, 10.1016[DOI]
125. Kwo PY, "An interferon-free antiviral regimen for HCV after liver transplantation", N Engl J Med, 371, pp.2375~2382 (2014)[DOI]
126. European Association for the Study of the Liver, "EASL Recommendations on treatment of hepatitis C 2016", J Hepatol, 66, pp.153~194 (2017)[DOI]
127. Martin P, "Hepatitis C virus and kidney disease", J Hepatol, 49, pp.613~624 (2008)[DOI]
128. Fabrizi F, "Meta-analysis: anti-viral therapy of hepatitis C virus-related liver disease in renal transplant patients", Aliment Pharmacol Ther, 24, pp.1413~1422 (2006)[DOI]
129. Cholongitas E, "Interferon-free regimens in patients with hepatitis C infection and renal dysfunction or kidney transplantation", World J Hepatol, 9, pp.180~ (2017)[DOI]
130. Bravo MJ, "HCV seroconversion among never-injecting heroin users at baseline: no predictors identified other than starting injection", Int J Drug Policy, 23, pp.415~419 (2012)[DOI]
131. Min JA, "Prevalence and associated clinical characteristics of hepatitis B, C, and HIV infections among injecting drug users in Korea", J Med Virol, 85, pp.575~582 (2013)[DOI]
132. Yun H, "High prevalence of HBV and HCV infection among intravenous drug users in Korea", J Med Virol, 80, pp.1570~1575 (2008)[DOI]
133. Dimova RB, "Determinants of hepatitis C virus treatment completion and efficacy in drug users assessed by meta-analysis", Clin Infect Dis, 56, pp.806~816 (2013)[DOI]
134. Lalezari J, "Ombitasvir", paritaprevir, J Hepatol, pp.2015, 63[DOI]
135. Dore GJ, "Elbasvir-grazoprevir to treat hepatitis C virus infection in persons receiving opioid agonist therapy: a randomized trial", Ann Intern Med, 165, pp.625~634 (2016)[DOI]
136. Grebely J, "Recommendations for the management of hepatitis C virus infection among people who inject drugs", Int J Drug Policy, 26, pp.1028~1038 (2015)[DOI]
137. Garimella T, "Assessment of drug-drug interactions between daclatasvir and methadone or buprenorphine-naloxone", Antimicrob Agents Chemother, 59, pp.5503~5510 (2015)[DOI]
138. Menon RM, "Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir", ritonavir, ombitasvir, and dasabuvir, 2015, pp.63, 20~29
139. Smolders EJ, "Drug-drug interactions between direct-acting antivirals and psychoactive medications", Clin Pharmacokinet, 55, pp.1471~1494 (2016)[DOI]
140. Liu CH, "Treatment of hepatitis C virus infection in patients with end-stage renal disease", J Gastroenterol Hepatol, 26, pp.228~239 (2011)[DOI]
141. 방병기, "신 이식 환자에서 B형과 C형 간염바이러스 감염 환자의 15년간 추적 조사", Kidney Research and Clinical Practice, 21(3), pp.423~434 (2002), 대한신장학회
142. Shin YH, "Prevalence of Anti-HCV in hemodialysis patients in Taegu and Kyeongbuk, Korea", Korean J Med, 54, pp.640~646 (1998)
143. Kim H, "Prevalence and risk factors of hepatitis C virus infection in chronic hamodialysis patients(multi-center study)", Korean J Med, 52, pp.833~840 (1997)
144. 진동찬, "Current characteristics of dialysis therapy in Korea: 2015 registry data focusing on elderly patients", Kidney Research and Clinical Practice, 35(4), pp.204~211 (2016), 대한신장학회
145. Kidney Disease: Improving Global Outcomes (KDIGO), "KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease", Kidney Int Suppl, (109), pp.S1~S99 (2008)
146. Lee JJ, "Hepatitis C virus infection increases risk of developing end-stage renal disease using competing risk analysis", PLoS One, 9, pp.e100790~ (2014)[DOI]
147. Fabrizi F, "Impact of hepatitis C on survival in dialysis patients: a link with cardiovascular mortality?", J Viral Hepat, 19, pp.601~607 (2012)[DOI]
148. Aroldi A, "Natural history of hepatitis B and C in renal allograft recipients", Transplantation, 79, pp.1132~1136 (2005)[DOI]
149. Bruchfeld A, "Hepatitis C infection, time in renal-replacement therapy, and outcome after kidney transplantation", Transplantation, 78, pp.745~750 (2004)
150. Choy BY, "Recurrent glomerulonephritis after kidney transplantation", Am J Transplant, 6, pp.2535~2542 (2006)[DOI]
151. Kamar N, "Diabetes mellitus after kidney transplantation: a French multicentre observational study", Nephrol Dial Transplant, 22, pp.1986~1993 (2007)[DOI]
152. Pockros PJ, "Efficacy of direct-acting antiviral combination for patients with hepatitis C virus genotype 1 infection and severe renal impairment or end-stage renal disease", Gastroenterology, 150, pp.1590~1598 (2016)[DOI]
153. Roth D, "Grazoprevir plus elbasvir in treatment-naive and treatmentexperienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study", Lancet, 386, pp.1537~1545 (2015)[DOI]
154. "Gastroenterology", 2017, S1062~S1063
155. Toyoda H, "Safety and efficacy of dual direct-acting antiviral therapy (daclatasvir and asunaprevir) for chronic hepatitis C virus genotype 1 infection in patients on hemodialysis", J Gastroenterol, 51, pp.741~747 (2016)[DOI]
156. Bruchfeld A, "Pegylated interferon and ribavirin treatment for hepatitis C in haemodialysis patients", J Viral Hepat, 13, pp.316~321 (2006)[DOI]
157. Mazzaro C, "Treatment with peg-interferon alfa-2b and ribavirin of hepatitis C virus-associated mixed cryoglobulinemia: a pilot study", J Hepatol, 42, pp.632~638 (2005)[DOI]
158. Saadoun D, "Antiviral therapy for hepatitis C virus--associated mixed cryoglobulinemia vasculitis: a long-term followup study", Arthritis Rheum, 54, pp.3696~3706 (2006)[DOI]
159. Saadoun D, "Efficacy and safety of sofosbuvir plus daclatasvir for treatment of HCV-associated cryoglobulinemia vasculitis", Gastroenterology, 153, pp.49~52 (2017)[DOI]
160. Sise ME, "Treatment of hepatitis C virus-associated mixed cryoglobulinemia with direct-acting antiviral agents", Hepatology, 63, pp.408~417 (2016)[DOI]
161. Sherman KE, "Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US adult AIDS clinical trials group", Clin Infect Dis, 34, pp.831~837 (2002)[DOI]
162. 이선희, "Trends of Mortality and Cause of Death among HIV-Infected Patients in Korea, 1990-2011", Journal of Korean Medical Science, 28(1), pp.67~73 (2013), 대한의학회
163. 이선희, "Causes of Death and Risk Factors for Mortality among HIVInfected Patients Receiving Antiretroviral Therapy in Korea", Journal of Korean Medical Science, 28(7), pp.990~997 (2013), 대한의학회
164. Bonacini M, "Effect of coexisting HIV-1 infection on the diagnosis and evaluation of hepatitis C virus", J Acquir Immune Defic Syndr, 26, pp.340~344 (2001)[DOI]
165. Bica I, "Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection", Clin Infect Dis, 32, pp.492~497 (2001)[DOI]
166. Thomas DL, "The natural history of hepatitis C virus infection: host, viral, and environmental factors", JAMA, 284, pp.450~456 (2000)
167. Torriani FJ, "Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients", N Engl J Med, 351, pp.438~450 (2004)[DOI]
168. Weber R, "Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study", Arch Intern Med, 166, pp.1632~1641 (2006)[DOI]
169. Qurishi N, "Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection", Lancet, 362, pp.1708~1713 (2003)[DOI]
170. Avidan NU, "Hepatitis C viral kinetics during treatment with peg IFN-alpha-2b in HIV", HCV coinfected patients as a function of baseline CD4+ T-cell counts, 2009, pp.52, 452~458
171. Sulkowski MS, "Rapid fibrosis progression among HIV", hepatitis C virus-co-infected adults, 2007, pp.21, 2209~2216
172. Tien PC, "Management and treatment of hepatitis C virus infection in HIV-infected adults: recommendations from the Veterans Affairs Hepatitis C Resource Center Program and National Hepatitis C Program Office", Am J Gastroenterol, 100, pp.2338~2354 (2005)[DOI]
173. Brau N, "Slower fibrosis progression in HIV", HCV-coinfected patients with successful HIV suppression using antiretroviral therapy, 2006, pp.44, 47~55
174. Macias J, "Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virus", hepatitis C virus, 2009, pp.50, 1056~1063
175. 대한에이즈학회, "국내 HIV 감염인의 HIV", AIDS 진단 및 치료에 관한 임상진료지침 권고안, 2011, pp.43(2), 89~128[DOI]
176. "DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents - A Working Group of the Office of AIDS Research Advisory Council (OARAC). Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents"[URL]
177. Sulkowski MS, "Management of acute and chronic HCV infection in persons with HIV coinfection", J Hepatol, 61(1 Suppl), pp.S108~S119 (2014)[DOI]
178. Alvarez D, "Zidovudine use but not weight-based ribavirin dosing impacts anaemia during HCV treatment in HIV-infected persons", J Viral Hepat, 13, pp.683~689 (2006)[DOI]
179. Lafeuillade A, "Increased mitochondrial toxicity with ribavirin in HIV", HCV coinfection, 2001, pp.357, 280~281
180. Salmon-Ceron D, "Mitochondrial toxic effects and ribavirin", Lancet, 357, pp.1803~1804 (2001)[DOI]
181. Osinusi A, "Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection", JAMA, 313, pp.1232~1239 (2015)[DOI]
182. Sulkowski MS, "Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial", JAMA, 313, pp.1223~1231 (2015)[DOI]
183. Naggie S, "Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1", N Engl J Med, 373, pp.705~713 (2015)[DOI]
184. Molina JM, "Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study", Lancet, 385, pp.1098~1106 (2015)[DOI]
185. Fernandez-Montero JV, "Management of hepatitis C in HIV and", or HBV co-infected patients, 2012, pp.26, 517~530
186. 김유진, "Clinical features and treatment efficacy of peginterferon alfa plus ribavirin in chronic hepatitis C patients coinfected with hepatitis B virus", Clinical and Molecular Hepatology, 17(3), pp.199~205 (2011), 대한간학회
187. Chiaramonte M, "Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis", Cancer, 85, pp.2132~2137 (1999)[DOI]
188. Lee LP, "Comparison of liver histopathology between chronic hepatitis C patients and chronic hepatitis B and C-coinfected patients", J Gastroenterol Hepatol, 22, pp.515~517 (2007)[DOI]
189. Sagnelli E, "Influence of chronic coinfection with hepatitis B and C virus on liver histology", Infection, 32, pp.144~148 (2004)[DOI]
190. Liu CJ, "Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses", Gastroenterology, 136, pp.496~504 (2009)[DOI]
191. Potthoff A, "The HEP-NET B", C co-infection trial: a prospective multicenter study to investigate the efficacy of pegylated interferon-alpha2b and ribavirin in patients with HBV, J Hepatol, pp.2008, 49[DOI]
192. Collins JM, "Hepatitis B virus reactivation during successful treatment of hepatitis C virus with sofosbuvir and simeprevir", Clin Infect Dis, 61, pp.1304~1306 (2015)[DOI]
193. Potthoff A, "Late hepatitis B virus relapse in patients co-infected with hepatitis B virus and hepatitis C virus after antiviral treatment with pegylated interferon-a2b and ribavirin", Scand J Gastroenterol, 44, pp.1487~1490 (2009)[DOI]
194. Belperio PS, "Evaluation of hepatitis B reactivation among 62,920 veterans treated with oral hepatitis C antivirals", Hepatology, 66, pp.27~36 (2017)[DOI]
195. Bersoff-Matcha SJ, "Hepatitis B virus reactivation associated with direct-acting antiviral therapy for chronic hepatitis C virus: a review of cases reported to the U.S. Food and Drug Administration adverse event reporting system", Ann Intern Med, 166, pp.792~798 (2017)[DOI]
196. Chen G, "Hepatitis B reactivation in hepatitis B and C coinfected patients treated with antiviral agents: a systematic review and meta-analysis", Hepatology, 66, pp.13~26 (2017)[DOI]
197. Omata M, "APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing", Hepatol Int, 10, pp.681~701 (2016)[DOI]
198. Plug I, "Mortality and causes of death in patients with hemophilia, 1992-2001: a prospective cohort study", J Thromb Haemost, 4, pp.510~516 (2006)[DOI]
199. Vento S, "Infections and thalassaemia", Lancet Infect Dis, 6, pp.226~233 (2006)[DOI]
200. Zhang M, "Correlates of spontaneous clearance of hepatitis C virus among people with hemophilia", Blood, 107, pp.892~897 (2006)
201. Hezode C, "Elbasvir", grazoprevir for patients with hepatitis C virus infection and inherited blood disorders: a phase III study, 2017, pp.66, 736~745
202. Ozguroglu M, "Reactivation of hepatitis B virus infection with cytotoxic therapy in non-Hodgkin's lymphoma", Med Oncol, 21, pp.67~72 (2004)[DOI]
203. Kawatani T, "Incidence of hepatitis virus infection and severe liver dysfunction in patients receiving chemotherapy for hematologic malignancies", Eur J Haematol, 67, pp.45~50 (2001)[DOI]
204. Markovic S, "Reactivation of hepatitis B but not hepatitis C in patients with malignant lymphoma and immunosuppressive therapy. A prospective study in 305 patients", Hepatogastroenterology, 46, pp.2925~2930 (1999)
205. Vento S, "Reactivation of replication of hepatitis B and C viruses after immunosuppressive therapy: an unresolved issue", Lancet Oncol, 3, pp.333~340 (2002)[DOI]
206. Faggioli P, "Acute hepatic toxicity during cyclic chemotherapy in non Hodgkin's lymphoma", Haematologica, 82, pp.38~42 (1997)
207. Nosotti L, "Hepatitis C virus infection prevalence and liver dysfunction in a cohort of B-cell non-Hodgkin's lymphoma patients treated with immunochemotherapy", Scand J Infect Dis, 44, pp.70~73 (2012)[DOI]
208. Takai S, "Prevalence of hepatitis B and C virus infection in haematological malignancies and liver injury following chemotherapy", Eur J Haematol, 74, pp.158~165 (2005)[DOI]
209. Fan FS, "Withdrawal of immunosuppressive therapy in allogeneic bone marrow transplantation reactivates chronic viral hepatitis C", Bone Marrow Transplant, 8, pp.417~420 (1991)
210. Melisko ME, "Reactivation of hepatitis C virus after chemotherapy for colon cancer", Clin Oncol (R Coll Radiol), 16, pp.204~205 (2004)[DOI]
211. Vento S, "Fulminant hepatitis on withdrawal of chemotherapy in carriers of hepatitis C virus", Lancet, 347, pp.92~93 (1996)[DOI]
212. Hamaguchi M, "Retrospective study on the impact of hepatitis B and hepatitis C virus infection on hematopoietic stem cell transplantation in Japan", Int J Hematol, 75, pp.324~331 (2002)[DOI]
213. Locasciulli A, "Hepatitis reactivation and liver failure in haemopoietic stem cell transplants for hepatitis B virus (HBV)", hepatitis C virus (HCV) positive recipients: a retrospective study by the Italian group for blood and marrow transplantation, 2003, pp.31, 295~300
214. Lee JM, "The prevalence of anti-HCV positivity in healthy Korean children", Korean J Hepatol, 2, pp.160~165 (1996)
215. Mohan P, "Evaluating progression of liver disease from repeat liver biopsies in children with chronic hepatitis C: a retrospective study", Hepatology, 58, pp.1580~1586 (2013)[DOI]
216. Okamoto M, "Prospective reevaluation of risk factors in mother-to-child transmission of hepatitis C virus: high virus load, vaginal delivery, and negative anti-NS4 antibody", J Infect Dis, 182, pp.1511~1514 (2000)[DOI]
217. Claret G, "Mother-to-child transmission of hepatitis C virus infection in Barcelona, Spain: a prospective study", Eur J Pediatr, 166, pp.1297~1299 (2007)[DOI]
218. 강문정, "임신 여성에서 C형 간염의 유병률과 수직 감염", Obstetrics & Gynecology Science, 47(11), pp.2045~2050 (2004), 대한산부인과학회
219. Kim YW, "Hepatitis C virus infection in pregnancy", Korean J Obstet Gynecol, 43, pp.597~603 (2000)
220. Pembrey L, "The management of HCV infected pregnant women and their children European paediatric HCV network", J Hepatol, 43, pp.515~525 (2005)[DOI]
221. "Hepatitis C virus infection. American Academy of Pediatrics. Committee on Infectious Diseases", Pediatrics, 101, pp.481~485 (1998)[DOI]
222. Mast EE, "Risk factors for perinatal transmission of hepatitis C virus (HCV) and the natural history of HCV infection acquired in infancy", J Infect Dis, 192, pp.1880~1889 (2005)[DOI]
223. Polywka S, "Accuracy of HCV-RNA PCR tests for diagnosis or exclusion of vertically acquired HCV infection", J Med Virol, 78, pp.305~310 (2006)[DOI]
224. Guido M, "Chronic hepatitis C in children: the pathological and clinical spectrum", Gastroenterology, 115, pp.1525~1529 (1998)[DOI]
225. Mack CL, "NASPGHAN practice guidelines: diagnosis and management of hepatitis C infection in infants, children, and adolescents", J Pediatr Gastroenterol Nutr, 54, pp.838~855 (2012)[DOI]
226. Balistreri WF, "The safety and effectiveness of ledipasvir-sofosbuvir in adolescents 12-17 years old with hepatitis C virus genotype 1 infection", Hepatology, 66, pp.371~378 (2017)[DOI]
227. Wirth S, "Peginterferon alfa-2b plus ribavirin treatment in children and adolescents with chronic hepatitis C", Hepatology, 41, pp.1013~1018 (2005)[DOI]
228. Wirth S, "High sustained virologic response rates in children with chronic hepatitis C receiving peginterferon alfa-2b plus ribavirin", J Hepatol, 52, pp.501~507 (2010)[DOI]
229. Schwarz KB, "The combination of ribavirin and peginterfer on is superior to peginterferon and placebo for children and adolescents with chronic hepatitis C", Gastroenterology, 140, pp.450~458 (2011)[DOI]
230. Akuta N, "Ledipasvir plus sofosbuvir as salvage therapy for HCV genotype 1 failures to prior NS5A inhibitors regimens", J Med Virol, 89, pp.1248~1254 (2017)[DOI]
231. "J Hepatol", 2015, S192~
232. Lawitz E, "Short-duration treatment with elbasvir", grazoprevir and sofosbuvir for hepatitis C: a randomized trial, 2017, pp.65, 439~450
233. Poordad F, "Ombitasvir", paritaprevir, J Hepatol, pp.2016, 64[DOI]
234. Bourliere M, "Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection", N Engl J Med, 376, pp.2134~2146 (2017)[DOI]
235. Gane EJ, "Sofosbuvir-velpatasvir with ribavirin for 24 weeks in hepatitis C virus patients previously treated with a direct-acting antiviral regimen", Hepatology, 66, pp.1083~1089 (2017)[DOI]
236. Poordad F, "Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment", Hepatology, 66, pp.389~397 (2017)[DOI]
237. "J Hepatol", 2017, S83~S84
238. "J Hepatol", 2017, S708~S709
239. Osinusi A, "Re-treatment of chronic hepatitis C virus genotype 1 infection after relapse: an open-label pilot study", Ann Intern Med, 161, pp.634~638 (2014)[DOI]
240. Wyles D, "Ledipasvir-sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimens", Hepatology, 61, pp.1793~1797 (2015)[DOI]
241. "Hepatology", 2016, 1128A~, 10.1016[DOI]
242. "Hepatology", 2016, 39A~

관련 논문AI추천